
The phase 3 priMe trial found the investigational vaccine did not demonstrate noninferiority for preventing tuberculosis infection, though the study authors cited surrogate end point and exposure-imbalance issues that complicate interpretation.
Researchers from the University of Pittsburgh find a way to successfully treat a patient with ceftazidime-avibactam-resistant Klebsiella pneumoniae.
Clinicians used meropenem to successfully treat a patient with bacteremia due to Klebsiella pneumoniae that carried a mutation in the blaKPC-3 gene, and was resistant to ceftazidime-avibactam.






